Evidence map›Paper›PMID 41741230›Full record

ReviewRNA (New York, N.Y.)2026

Genetic and genomic approaches to explore roles for the conserved 3'-5' exoribonuclease EXOSC10 in normal and malignant cells.

Radhika Sain, Julian Primig, Michael Primig

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in RNA (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Radhika SainUniversité de Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail)-UMR_S 1085, Rennes F-35042, France.ORCID 0009-0001-6529-3452
Julian PrimigFaculté des Sciences et Ingénierie, Sorbonne Université, Paris F-75005, France.ORCID 0009-0000-8394-854X
Michael PrimigUniversité de Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail)-UMR_S 1085, Rennes F-35042, France michael.primig@inserm.fr.ORCID 0000-0002-2061-0119

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

EXOSC10 is a conserved 3'-5' exoribonuclease involved in processing ribosomal RNAs and degrading coding and noncoding transcripts as a catalytic subunit of the nuclear RNA exosome and in cooperation with cofactors. The protein is posttranslationally modified and shuttles between the nucleolus and the nucleus in response to oxygen deprivation in a process that involves sumoylation. EXOSC10 is of medical interest because its activity is inhibited by the anticancer drug 5-fluorouracil, which interferes with DNA replication and RNA-dependent processes. Moreover, high expression of

Indexed as

ExoribonucleasesExosome Multienzyme Ribonuclease ComplexNeoplasmsAnimalsGene Expression Regulation, NeoplasticGenomicsHumansMiceExoribonucleasesEXOSC10 protein, humanExosome Multienzyme Ribonuclease ComplexcancerEXOSC10prognostic cancer biomarkerRNA exosomeRrp6

Identifiers

PMID41741230
PMCPMC13182612

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.